Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

COMMENTED

Inflammatory Bowel Disease

Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

Inflamm Bowel Dis.

Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS

doi: 10.1093/ibd/izy307.

Inflammatory Bowel Disease

Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment

Inflamm Bowel Dis

Lee SH, Walshe M, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Greener T, Weizman AV, Silverberg MS, Ye BD

doi: 10.1093/ibd/izaa309

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Am J Gastroenterol.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS

doi: 10.1038/s41395-018-0162-0.

Inflammatory Bowel Disease

A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis

Inflamm Bowel Dis.

Dalal RS, Osterman MT, Buchner AM, Praestgaard A, Lewis JD, Lichtenstein GR

doi: 10.1093/ibd/izz014.

Inflammatory Bowel Disease

The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis

Inflamm Bowel Dis.

Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, Manship TA, Jagger FAM, Brindle WM, Shivakumar M, Satsangi J, Arnott IDR

doi: 10.1093/ibd/izaa088.

Inflammatory Bowel Disease

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review

BMC Gastroenterol.

Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R

doi: 10.1186/s12876-020-01332-w.

Inflammatory Bowel Disease

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Inflamm Bowel Dis.

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S

doi: 10.1093/ibd/izy323.

Inflammatory Bowel Disease

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

United European Gastroenterol J.

Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F

doi: 10.1177/2050640619895361.

Inflammatory Bowel Disease

Development and validation of a patient-reported score to screen for mucosal inflammation in inflammatory bowel disease

J Crohns Colitis.

de Jong MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, Romberg M, Hameeteman W, Bodelier AGL, Romanko I, Lukas M5, Winkens B, Markus T, Masclee AAM, van Tubergen A, Jonkers DMAE, Pierik MJ

doi: 10.1093/ecco-jcc/jjy196.

Related content

Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis

The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

Development and validation of a patient-reported score to screen for mucosal inflammation in inflammatory bowel disease